# Structure of Two in Tandem Human $17\beta$ -Hydroxysteroid Dehydrogenase Genes

Van Luu-The, Claude Labrie, Jacques Simard, Yves Lachance, Hui-Fen Zhao, Jacques Couët, Gilles Leblanc, and Fernand Labrie

Medical Research Council Group in Molecular Endocrinology Research Centre Laval University Medical Centre Québec, G1V 4G2, Canada

Two human  $17\beta$ -hydroxysteroid dehydrogenase (17 $\beta$ -HSD) genes (h17 $\beta$ -HSDI and h17 $\beta$ -HSDII) included in tandem within an approximately 13 kilobase pair fragment were isolated from a genomic  $\lambda$ EMBL3 DNA library using cDNA encoding human  $17\beta$ -HSD (hpE<sub>2</sub>DH216) as probe. We have determined the complete exon and intron sequences of the two genes as well as their 5' and 3'-flanking regions. Human 178-HSDII contains six exons and five short introns for a total length of 3250 base pairs. The exon sequence of  $h17\beta$ -HSDII is identical to the previously reported hpE<sub>2</sub>DH216 cDNA while the overlapping nucleotide sequences of the corresponding exons and introns of h17 $\beta$ -HSDI and h17 $\beta$ -HSDII show 89% homology. In addition, we have used the hpE<sub>2</sub>DH216 cDNA to demonstrate the widespread expression of 17*β*-HSD mRNAs in steroidogenic and peripheral target tissues. These new findings provide the basis for a better understanding of the molecular mechanisms involved in 17β-HSD deficiency and peripheral sex steroid metabolism. (Molecular Endocrinology 4: 268-275, 1990)

# INTRODUCTION

Estradiol 17 $\beta$ -dehydrogenase (EC1.1.1.62) (1, 2), also known as 17 $\beta$ -hydroxysteroid dehydrogenase (17 $\beta$ -HSD) (3), catalyzes the interconversion of the following 17-ketosteroids and their 17 $\beta$ -hydroxysteroid counterparts: estrone and 17 $\beta$ -estradiol, dehydroepiandrosterone and 5-androstene-3 $\beta$ ,17 $\beta$ -diol, androstenedione and testosterone, androstane-3,17-dione and 5 $\alpha$ -dihydrotestosterone, androsterone and androstane-3 $\alpha$ , 17 $\beta$ -diol, as well as 3-epiandrosterone and androstane-3 $\beta$ ,17 $\beta$ -diol. The enzyme 17 $\beta$ -HSD is present in a series of human tissues, including the placenta (4), testis (4, 5), endometrium (6), vaginal mucosa (7), lung (8), liver (9), ileum (5), adipose tissue (10), skin (7), red blood

0888-8809/90/0268-0275\$02.00/0 Molecular Endocrinology Copyright © 1990 by The Endocrine Society cells (11), breast cancer cells (12), and prostatic cancer cells (13). Previously, we have isolated and characterized cDNAs for human placental  $17\beta$ -HSD (2). The existence of two mRNA species which differ only in their 5'-noncoding regions was then demonstrated and a unique primary structure of 327 amino acid residues has been deduced from the nucleotide sequence. Using  $17\beta$ -HSD cDNA (clone hpE<sub>2</sub>DH216) as a probe, we have isolated, sequenced and characterized two in tandem  $17\beta$ -HSD genes which reside within a 13 kilobase pair (kbp) genomic DNA fragment.

## **RESULTS AND DISCUSSION**

## **Cloning and Nucleotide Sequencing**

A human genomic DNA library constructed in  $\lambda$  EMBL3 phage vector was screened with a <sup>32</sup>P-labeled human placental 17<sub>β</sub>-HSD cDNA (hpE<sub>2</sub>DH216) as probe (2). Three positive clones were obtained from  $5 \times 10^5$ recombinants. Clones  $\lambda 17\beta$ -HSD29 and  $\lambda 17\beta$ -HSD14 possess identical inserts of approximately 13 kbp while the third clone,  $\lambda 17\beta$ -HSD2, consists of an overlapping genomic fragment of approximately 7 kbp contained within the longer clones (Fig. 1A). The fragments resulting from digestion of  $\lambda 17\beta$ -HSD29 with Sacl, Pstl, and BamHI were purified and subcloned into the Bluescript SK vector and sequenced in both directions (Fig. 1A). The merged sequence contains two  $17\beta$ -HSD genes (h17 $\beta$ -HSDI and h17 $\beta$ -HSDII) located in tandem within approximately 13 kbp human genomic fragment. The h17 $\beta$ -HSDII gene consists of 6 exons and 5 introns (Fig. 1B) and its exonic sequence is identical to the hpE<sub>2</sub>DH216 cDNA sequence previously reported (2). The complete nucleotide sequence of the human 17β-HSDII gene and the deduced amino acid sequence of its coding region are presented in Fig. 2. The nucleotide sequences adjoining the splice junctions are consistent with the recognized consensus sequence (14).

Comparison of the nucleotide sequence of  $h17\beta$ -HSDI with that of the exons and introns of the  $h17\beta$ -HSDII gene (Fig. 2) shows 89% homology. In analogy




Fig. 1. Structure and Restriction Map of Human h17β-HSD Genes

A, Restriction map of an approximately 13 kbp human genomic fragment containing h17β-HSDI and h17β-HSDI genes. Sizes of fragments isolated from three  $\lambda$ EMBL3 recombinant clones are indicated above while *SacI*, *BamHI*, and *PstI* restricted fragments subcloned in Bluescript SK as well as the sequenced regions (*shadowed boxes*) corresponding to h 17β-HSDI and h17β-HSDI genes are shown below the map. B, Exon-intron organization and restriction map of h17β-HSDI gene. Exons are represented by boxes and numbered from I to VI. *Shaded box areas* indicate noncoding regions. Nontranscribed regions are represented by the *solid line*. Exon and intron sizes are indicated below the schematic h17β-HSDI gene.

with gene h17 $\beta$ -HSDII, gene h17 $\beta$ -HSDI could be potentially transcribed, spliced at the same exon-intron junctions and translated from the first corresponding inframe ATG codon position. However, due to a change from a G to a T, thus creating a TAA stop codon rather than encoding for the amino acid Gln at position 218, gene h17 $\beta$ -HSDI potentially encodes a protein of 214 amino acids (including the first Met).

Southern blot analysis (Fig. 3) was performed using the <sup>32</sup>P-labeled hpE<sub>2</sub>DH216 cDNA fragment (nucleotides 0 - 1892) as probe. The restriction patterns obtained with BamHI shows three fragments of about 1, 5. and 9.4 kb which could well correspond to the fragments found in the human genomic fragment of the two h17 $\beta$ -HSD genes (Fig. 1). The difference between the 4 kb DNA fragments obtained by restriction mapping of  $\lambda 17\beta$ -HSD29 and the approximately 9.4 kb band observed by Southern blot analysis suggests that the BamHI site at the 3'-end of the genomic clone is generated by cloning since human genomic DNA was partially digested with Sau3AI before insertion in the BamHI site of  $\lambda$ EMBL3. The digestion pattern of PstI also yields the two strongly hybridizing (~1 and 2 kb) fragments expected from restriction mapping of the h17β-HSDII gene. An additional faint band at approximately 0.9 kb and another band of approximately 1.7 kb obtained after a longer exposure time (data not shown) could well correspond to the Pstl fragments

found in the h17 $\beta$ -HSDI gene. Furthermore, digestion with EcoRI which cuts once in h17 $\beta$  HSDI gave rise to two doublets of 18 kb and 15.5 kb. In addition, digestion with *Hind*III which cuts once in the 5' and 3'-flanking region of both h17 $\beta$ -HSDI and h17 $\beta$ -HSDI produced a doublet of approximately 5.1 and 5.3 kb. Our recent demonstration of the unique chromosomal assignment of 17 $\beta$ -HSD gene to the q12 band of chromosome 17 (2) coupled with the data from Southern blot analysis thus agree with the existence of the two genes described in Fig. 2. In addition, digestion of human genomic DNA with *XbaI* indicates that the two genes are included in one fragment of greater than 23 kb.

Two mRNA species have been identified in poly(A) RNA from human placenta, namely a major species of 1.3 kb and a minor one of 2.2 kb (2).  $S_1$  analysis indicates that the major mRNA starts nine nucleotides upstream of the starting codon while the minor mRNA species contains approximately 971 nucleotides upstream from the in frame ATG initiating codon (Fig. 4).

Primer extension analysis (2) confirmed the position of the cap site of the short mRNA as determined by S1 nuclease protection experiment (Fig. 4). Since the transcription start site of the long mRNA agrees with an observed mRNA size of 2.2 kb (2) and no AG consensus sequence for an intron-exon splice site is found up to 65 bp upstream from the potential cap site, it is unlikely that the S<sub>1</sub> nuclease-protected fragment ends at an

269

-GATEC-CETG-C-CGGECT-CCA h17B-HSD 1 - СТСССТТСААТТАСАGСАGТАGCCTCCTААСТАGTTTTCTTGATTCCACTCTTGCCCATCAGCAGTGAAATTACCCCAGGGCAGTTAAAATGATCTTTTAGGATGGC-	1751
A-GT-CTGGGATTACAGGAGTGAGCCCCCCAT-TCTTT-TAA-ACTAA-GTTACCC-G-CCTTTGAA-GT-GA-TGCCCTTTGTG-AGGAAAACCTTTTC-A CACAGTGTCACGGCTGTAATACCAGGAGCTTTGGGAGGTGGAGGCTGGGGGTGTAGGGAGGTGGAGGAGCATCCACCAACAGGGGGGAGAAACCCCATCTCTACTAAAAATACA-1	1631
CC-TG-TTGTC-T-TGCTG-C-TGCCACAGCA-CAGTC-AACA-AA-TCTGTGACCATATT-GGGATTTTCCCCAC-CACACAGCAGAC-TCATGGGTGTG- AAAATTAGCCGCATGTGGTGGAACGTGTCTGTAATCCCAACTACTTGGGAGGTGAGGCAGAGAACTGCTTGAACCCGGGAGGTGGAGGTTGCAGTGCAGGAGCCAGAACGTGCCACAGCACT-1	1511
T-CANT-CA-TTCCTCTANTC-AC-A-AGAGCC-GCCCACAGGGTT-GG-TGCA-AT-CATGA-ACCAC-C-C-C-C-C-A-G-TTACAAG-CCTGAT-CGT-AACTTC CCAGCCTGGGCAAGAAGCGCGAAACTCCGTCTCAAAATAAAATAAACTTCTAAAAATGACAGGGCCAGGTGGGGTGGGCACTTTTTTATAATCCGAGCACTTTGGGAGGCTGAGGTGGGCA-1	1391
TGA-TANCTGGC-TCAA-T-GGAGTTCATCACCCTTCCCC-CTTTGGAGTCAACA-TTGCGACAGTG-CCCAC-AAACA-AGAAA-CCT-AATATGTT-ATTGCT-TA-TAC GATCGCTTGACATCAGGGGTTTGAGACCAGCCTGGCCAACATGGTGAAACTCCGTCTACTAAAAATACTAAAAATAGCTGGGGGGGG	1271
АСА-САА-ААА-ТТТТТТТТТСТТТТТ-АС-С-G-GTCTCACTCTGTCAT-CА-G-CTGCAGTGG-AGG-T-TGGCT-CG-CACCCAGGCTGG-GTGC-GTGGC-TGA-CTCGG САСОСТСАТССАССАСААТССССТСААССАССАСАСАСАС	1151
CTC-CTAC-CC-TAC-CCCCCCCCACGCCTCAGCCCCACGCC-CAAGT-GCTGACTCT-AGCACAACCACCCA-CT-ATTTGGG ACAAAGTGAGACCCCGTCTCTACAAAAAAACTCAAAAAATTAGCTGGGGTATGGGGAGTGGCAGTGGAAGCCCGTGTAGTCCCGGCTACTTGGGAAGCTTTTTAATATTTTTGGGAGAGCC-1	1031
دو٩٩-۵ ۵۲۵۲۵۵۵۵۵۵	
GGGTCTCACTCTGTTACCTGGCCTGGTCTTGAACTCCTGGGCTCCAACAATCCCCTTTCCTGGGCCTCCCAAAGTGCTGGGATTAGAGGCATGAGCCACCGTGGCCCAGGCCTCAAAGCATC GGATGAGTTCTTCACCT	-911
	-791
CTGTCAGCCTCCACACGTTCAGCTCTCAGAAGCTCCCGAACCCCTGTCCTTTGGGCCATTGGAGAACTCCATTGGCTGCAGCAAGCA	~671
GCAAAAAGGGTCTGATCTAAGCCCAGCAAGGCCAGTCCAGATTCTTTGGGCCTTTGTGCAGCATTCCTTTCTCCAGGGTATGGGGCAAGGACCCACTCTGGAATGAGGATCCTACAACCC	-551
GGGGG	-431
	-311
ТТТТТТ	-191
GGG	-71
CAP-S I	
CCCCCCAGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG	36
TCG GGC ATC GGC CTG CAC TTG GCC GTA CGT CTG GCT TCA GAT CCA TCC CAG AGC TTC AAA G GTATAGATAGGCAGGGAGGAGGAGGGAGGAGGGAGGGAGG	135
AGCCCTTGGAGGCTAGAAGGGAAGTCAGATCTTCCTCCTCCCCAAAACCTCCAG TG TAT GCC ACG TTG AGG GAC CTG AAA ACA CAG GGC CGG CTG TGG GAG al Tyr Ala Thr Leu Arg Asp Leu Lys Thr Gin Giy Arg Leu Trp Giu 40	237
GCG GCC CGG GCC CTG GCA TGC CCT GCG GGA TCC CTG GAG ACG TTG CAG CTG GAC GTA AGG GAC TCA AAA TCC GTG GCC GCT GCC CGG GAA Ala Ala Arg Ala Leu Ala Cys Pro Pro Gly Ser Leu Glu Thr Leu Gln Leu Asp Val Arg Asp Ser Lys Ser Val Ala Ala Ala Ala Arg Glu 50 70	327
CGC GTG ACT GAG GGC GGC GTG GAC GTG CTG G GTGAGGCTCCTGGAAGCATATGGGCTCCTAGGAGCCTTGTGGGCCCTGGGTTGAAACCAAGATGTTGCCAGGCCCAGG Arg val Thr Glu Gly arg val asp val Leu v 80	436
GAGCACGAGGGGACAGGCCGTGCTGAGGGGGTGATGCTGAGGCGGGCTGGTCGGGCCTGTTGTCTCCGCAG TG TGT AAC GCA GGC CTG GGC CTG CTG GGG CCG CTG GAG al Cys Asn Ala Gly Leu Gly Leu Gly Pro Leu Glu 90 100	543
GCG CTG GGG GAG GAC GCC GTG GCC TCT JTG CTG GAC GTG AAT GTA GTA GGA ACT GTG CGG ATG CTG CAG GCC TTC CTG CCA GAC ATG AAG Ala Leu Gly Glu Asp Ala Val Ala Ser Vai Leu Asp Val Asn Val Val Gly Thr Val Arg Met Leu Gln Ala Phe Leu Pro Asp Met Lys 110 120 120	633
C GC CCCG-C-*CGA AGG CGC GGT TCG GGA CGC GTG TTG GTG ACC GGG AGC GTG GGA GGA TTG ATG G GTGAGTGGTAGGGAGTGGCCTCGGCAGCTCCAGATTCTTTGTGTGCGGAG Arg Arg Gly Ser Gly Arg Val Leu Val Thr Gly Ser Val Gly Gly Leu Met G 140	735
CCCA	855
CTAAG GG CTG CCT TTC AAT GAC GTT TAT TGC GCC AGG AAG TTC GCG CTC GAA GGC TTA TGC GAG AGT CTG GCG GTT CTG CTG CTG CTC TTT iy Leu Pro Phe Asn Asp Val Tyr Cys Ala Ser Lys Phe Ala Leu Glu Gly Leu Cys Glu Ser Leu Ala Val Leu Leu Leu Pro Phe 150 160 170	946
GGG GTC CA GTGAGTCAACACCCCCGTTCCCCGAACCCTCTTAACTCTGACCTAGAGATGCCGAGCACCCTGTCCTGCGGGAGCCGCTCTGGGGCGATCTCCCTGGGCCCTCTCTGCCC 1 G1y Val Hi 180	1063
TC	1183
	1303
ТС-АКККККТТТС-АС-АКККККККК-	1423

1612 CCC CCC CCC CCC CCC CCC CCC CCC CCC C	CCTGGCTGGCGTCCGCCCCCCCCCCCCCCCCCCCCCCC	
$\frac{\text{CCC}}{\text{CCC}} \frac{\text{CCC}}{\text{CCC}} \frac{\text{CCC}}{\text{CC}} \frac{\text{CCC}}{\text{CCC}} \frac{\text{CCC}}{\text{CCC}} \frac{\text{CCC}}{\text{CC}} \frac{\text{CCC}}{\text{CC}} \text{CC$	TTG GGC AGC CCA GAG GAG GTG CTC GAC CGC ACG GAC ATC CAC ACC TTC CAC CGC TTC TAC CAA TAC CTC GCC CAC AGC AAG CAA GTC TTT 1612 Lou Gly Ser Pro Glu Glu Val Leu Asp Arg Thr Asp 11e His Thr Phe His Arg Phe Tyr Gln Tyr Leu Ala His Ser Lys Gln Val Phe	
TCCCGCCGCGCG GTC TTC CTC ACC GCT TTG CGC GCC CGC AAG CCC ACC CTT CTC CCC TAC CCC ACC CGC CGC CGC CGC CGC CGC CGC C	CCC GAG GCG GCG GAG AAC CCT GAG GAG GTG GCG GAG GTGAGCGCCGGGCTGGACTCCAGGAGTGGGGGGGGGG	
ATG CGC CTG GAC GAC CCC AGC GGC TCC AAC TAC TAC GTC ACC GCC ATG CAC CGC ATG CAC CGG GAA GTG TTC GGC GAT GTT CGC GAA AGG CCC GAG GCT GGG 1902 Net Arg Leu Asp Asp Pro Ser Gly Ser Asn Tyr Val Thr Ala Met His Arg Glu Val Phe Gly Asp Val Pro Ala Lys Ala Glu Ala Gly 280 	TCCCGCCGCCGCAG GTC TTC CTC ACC GCT TTG CGC GCC CCG AAG CCG ACC CTG CGC TAC TTC ACC ACC GAG GGC TTC CTG CCC CTG CTG CGG 1812 Val Phe Leu Thr Ala Leu Arg Ala Pro Lys Pro Thr Leu Arg Tyr Phe Thr Thr Glu Arg Phe Leu Pro Leu Leu Arg	
$\frac{1}{1}$	ATG CGC CTG GAC GAC CCC AGC GGC TCC AAC TAC GTC ACC GCC ATG CAC CGG GAA GTG TTC GGC GAC GTT CCG GCA AAG GCC GAG GCT GGG 1902 Met Arg Leu Asp Asp Pro Ser Gly Ser Asn Tyr Val Thr Ala Met His Arg Glu Val Phe Gly Asp Val Pro Ala Lys Ala Glu Ala Gly	
$ \begin{array}{c} \text{GCC} \text{CCC} \text{CCC} \text{CAC} \text{TAA} AGGCTTCCTCAGCCGCTGTCTCCCCGGGCCCTTTTTTGCCCCTGGGCTCGTGGGCTCGGGGCGGC$	CC CAG GCT GGG GGC GGG GCC GGG CCT GGG GCA GAG GAC GAG GCC GGG GGC AGT GCG GGG GGC GCG GGC GCC GGG GCC CCT GAG CCT CCG GCC 1992 Ala Clu Ala Cly Cly Cly Ala Cly Pro Cly Ala Clu Asp Clu Ala Cly Asp Ser Ala Val Cly Asp Pro Clu Leu Cly Asp Pro Pro Ala	
GATCGCGTTAGCCAGTTTTACCAGCGGAGGGGATGGCGGATGGCGCATGGCGCTGTGGCGCGGGGGGGG	GCC CCG CAG TAA AGGCTTCCTCAGCCGCTGTCTCCCCGCGCCCCTTCTTTGTCCCCCTGGGGTCTGTGTGGGCGGGGGG	
GCAACCACAGTGAGACCCCCATCTCTACAAAAATAAAAAAATTTAAAAATTTAAAAATCAGCACAGTGGCACCATTGCTTGAGCCCCAGGAGTGGAGGGGGCAGTGGGGCATGGGGCCATGGGGCCAGGGGCCAGGGGGGCAGGGGGGCAGGGGGGCAGGGGGG		
	GCAACACAGTGAGACCCCCATCTCTACAAAAATAAAGAAAATTTAAAAATCAGCACAGTGGCACCATTCCTTGAGCCCAGGAGTTGGAGGGTGCAGTGAGCATGATGGGGCCACTGCACT 2348	i
AGGCCAGACACAGGCCTCGGACTCCGAGGGGCATCTGCAGGAGGAGTTAGGGGGAATTGGGGTAGAGTCAGGGTAGAGTCAGGGTCTGGACTTGGACCCAGTGAGCCAGGACCCAGGGGCAGGGGAAGTCGGGGAAGGGGGAAGGGGGCAAGGGGGCAAGGGGGCAAGGGGGCAAGGGGGCAAGGGGGG	TT	;
CANTCICCGCTTCCCAGATTCAAGTGATTCTCCTGGCCTCAGCCTCCCAAGTAGGTGGGATACGGCTAAGATTTGTATGTTCGGTAGAGACGGGGTTTCTCCATGTTGGTCAGGCCAGGGTTTCTC CAAACICTCGACCTTGGTGATCCGACCGCCTCGGCCTCCAGATTGCTGGGCATCGGCGATGAGCACCGGGACCGGCCCTCTGAGTCTTTTTTTGTGAAAATGGGTATATAATACCTAT 2948		
CANACICTCGACCTTGGTGATCCGACCGCCTCGGCCTCTCAGATTGCTGGGCATCGGCATGAGCACCGCGACCGGCCCTCTGAGTCTTTCTT	GITCCTTGCTTTCTCTCTCTTTCTTTCTTTCTTTCTTTCT	
	CAATCTCCGCTTCCCAGATTCAAGTGATTCTCCTGCCTCAGCTCCCAAGTAGGTGGGATACGGCTAAGATTTGTATGTTCGGTAGAGACGGGGTTTCTCCATGTTGGTCAGGCTGGTCT 2828	
CTAAACGETTTTAGTAATGETGEAGATAT	CAAACICTCGACCTTGGTGATCCGACCGCCTCGGCCTCTCAGATTGCTGGGCATCGGCATGAGCACCGCGACCGGCCCTCTGAGTCTTTCTT	1
	CTAAACGCTTTTAGTAATGGTCGAGATAT	

Fig. 2. Alignment of Nucleotide Sequences of the h17 $\beta$ -HSDI and h17 $\beta$ -HSDII Genes

Numbers on the right correspond to nucleotide positions in h17 $\beta$ -HSDI beginning with the translation initiation codon labeled as +1. Amino acid residues are shown below the nucleotide sequence and numbered below the sequence. CAP sites for the long (L) and short (S) mRNA transcripts of h17 $\beta$ -HSDI gene are indicated. The nucleotide sequence of h17 $\beta$ -HSDI is indicated above that of h17 $\beta$ -HSDI. Dashed line (---) and *asterisks* (\*\*\*) indicate identical and missing nucleotides, respectively. Additional nucleotides are indicated in *brackets*.

exon-intron junction. As observed in the nucleotide sequences of the 5' noncoding region of placental  $17\beta$ -HSD cDNAs (2), it can be seen that the cap site for the short mRNA is preceeded upstream by a TATA box-like motif (ATATCAA) (15, 16), a GC box (GGGGCGGGGGC) (17, 18) and a putative inverse CAAT box (GATTG) (19) at 32, 52, and 93 nucleotides, respectively.

We subsequently studied the distribution of  $17\beta$ -HSD mRNAs in a series of human tissues. All of the tissues studied contain the 2.2 kb mRNA species (Fig. 5). As mentioned above, this transcript has been shown to contain an extended 5'-noncoding region as evidenced by the signal resulting from hybridization of the placental poly(A)\* RNA with the <sup>32</sup>P-labeled EcoRI-Ncol fragment which corresponds to the 5'-noncoding region of hp-E<sub>2</sub>DH216 cDNA (2). The 2.2 kb mRNA species is predominant in myometrial, endometrial, prostatic, and abdominal fat tissues. The 1.3 kb  $17\beta$ -HSD mRNA, on the other hand, is very abundant in the placenta and ovary while it is present to a lesser extent in testicular tissue. Shorter transcripts are detectable in endometrial, mammary, testicular and prostatic tissues as well as ZR-75-1 and LNCaP cancer cells.

As expected,  $17\beta$ -HSD mRNAs are expressed in known steroidogenic tissues such as the ovary, testis, and placenta. More interestingly, the appreciable level of expression of  $17\beta$ -HSD mRNAs in peripheral tissues such as the uterus, breast, prostate, and fat indicates that  $17\beta$ -HSD could play an important role in regulating the activity of sex steroids in target tissues by locally synthesizing active androgens and estrogens from inactive adrenal precursors.

It is thus likely that  $17\beta$ -HSD plays a major role in breast and prostate development and functions as well as in the growth of breast and prostate cancer (20–22). While h17 $\beta$ -HSDII encodes an enzyme having preferential activity for estrogens (2), h17 $\beta$ -HSDI could possibly encode the proposed androgen-specific form of 17 $\beta$ -HSD (3) or simply be a pseudogene.

Cloning of the 17 $\beta$ -HSD genes offers the possibility of studying in detail the interaction between transcriptional factors and cis-acting elements responsible for the tissue specificity and hormonal regulation of 17 $\beta$ -HSD expression. It also offers the possibility of studying the molecular basis for the genetic deficiency of 17 $\beta$ -HSD in the human (23).




Fig. 3. Southern-Blot Hybridization Analysis of Human Genomic DNA with Human  $17\beta$ -HSD cDNA Probe

Ten micrograms of genomic DNA isolated from venous blood were digested with *Bam*HI, *Eco*RI, *Hind*III, *Pst*I, or *XbaI* and subjected to electrophoresis in 0.7% agarose gel. Southern blot analysis was performed as described in *Materials and Methods* using the <sup>32</sup>P-labeled *Eco*RI *PvuII* fragment (nucleotides 0-1892) of clone hpE<sub>2</sub>DH216 (2). *Bst*EII-digested  $\lambda$  DNA as well as the two larger *Hind*III-digested  $\lambda$  DNA fragments were used as molecular size markers.

## MATERIALS AND METHODS

### Screening of the Human Genomic DNA Library

The human leucocyte genomic DNA  $\lambda$ EMBL3 library (amplified once) was obtained from Clontech Laboratories Inc. (Palo Alto, CA). Screening was performed with the hpE<sub>2</sub>DH 216 cDNA probe (2). Hybridization and washing conditions were as described (2, 24).

#### **DNA Sequencing**

Fragments were subcloned in the Bluescript SK vector (Stratagene, San Diego, CA) and synthetic oligonucleotides were used as sequencing primers. The cDNA sequences were determined using the dideoxy chain termination method (25) with modified T7 DNA polymerase (26) (Sequenase kit, United States Biochemical Corp., Cleveland, OH).

#### S<sub>1</sub> Nuclease Analysis


The indicated amount of human placental poly(A)+ RNA was hybridized with the indicated 5'-end-labeled probe in 20  $\mu$ l buffer containing 80% formamide, 0.4 M NaCl, 40 mm 1,4piperazinediethanesulfonic acid (pH 6.4), and 1 mm EDTA (27). End labeling was performed by incubating the synthetic oligonucleotide primer with polynucleotide kinase and  $[\gamma^{-32}P]$ ATP (4000 Ci/mmol, Amersham, Arlington Heights, IL) while the probe was prepared by synthesizing the complementary strand of the 17β-HSD DNA template with the Klenow fragment of Escherichia coli polymerase 1. The synthesized single strand probe was separated from the template plasmid and free nucleotides by electrophoresis in 1.2% low-melting temperature agarose gel in alkaline buffer. After overnight hybridization at 30 C, the sample was diluted with 300 µl ice-cold buffer containing 50 mM sodium acetate (pH 4.5), 4.5 mM ZnSO<sub>4</sub>, 280 mm NaCl, 10 μg/ml tRNA, and digested with 400 U S<sub>1</sub> nuclease for 1 h at 30 C. Protected fragments were resolved by electrophoresis in polyacrylamide urea denaturing gel and visualized by autoradiography.

#### **Southern Blot Analysis**

Human DNA prepared from venous blood as described (28) was digested with a series of restriction endonucleases under the conditions specified by the supplier. The resulting DNA fragments were separated by electrophoresis in 0.7% agarose gels overnight at 3 V/cm gel length and transferred to nylon membranes (Hybond N, Amersham) as described (29). Filters were then prehybridized overnight at 42 C in 50% (vol/vol) formamide, 5× SSPE (1× SSPE being 0.18 м NaCl, 10 mм NaH<sub>2</sub>PO<sub>4</sub>, pH 7.4, 1 mm EDTA, 0.1% (wt/vol) sodium dodecyl sulfate (SDS), 0.1% (wt/vol) BSA, 0.1% (wt/vol) Ficoll, 0.1% polyvinyl-pyrrolidone, 200  $\mu$ g/ml denatured salmon testis DNA, 200 µg/ml yeast transfer RNA, and 20 µg/ml poly (A). The hpE2DH216 cDNA fragment ranging from the EcoRI cloning site to the last Pvull restriction site (0-1892) fragment was labeled with [32P]dCTP (3000 Ci/mmol; Amersham) by the random primer method (30) to a specific activity of  $1 \times 10^9$  $dpm/\mu q$ . The cDNA fragment was treated at 100 C for 5 min and  $2 \times 10^6$  cpm [<sup>32</sup>P]cDNA probe(s)/ml were added to fresh prehybridization buffer containing 4% (wt/vol) dextran sulfate. After 18 h of hybridization at 42 C, the filters were washed twice (30 min each) in 2× SSC with 0.1% SDS at 25 C and twice (30 min each) at 65 C in 0.1× SSC and 0.1% SDS. Autoradiography was performed at -80 C using XAR-5 films in the presence of two Quanta III intensifying screens for 3 days.

#### **RNA Blot Analysis**

Term placental tissue, as well as normal ovaries, myometrium, endometrium, mammary tissue, and abdominal fat were removed from otherwise healthy adult women during routine surgical procedures. Prostatic tissue was obtained from men undergoing prostatectomy for benign prostatic hyperplasia while testicular tissue was removed for the treatment of prostate cancer. ZR-75-1 human breast cancer cells and LNCaP human prostatic cancer cells were grown as described (12, 13). Total RNA was extracted by the guanidinium isothiocyanate cesium chloride centrifugation method (31) and





Poly(A)<sup>+</sup> RNA (3  $\mu$ g in A and 2 or 5  $\mu$ g in B) from human placenta was used to protect the single strand probe (synthesized according to *Materials and Methods*) from S<sub>1</sub> nuclease digestion. Probe using primer starting at position -786 to -810 (A), Probe using primer starting at position +92 to +76 (B). Lane 1, protected fragment; lane 2, digested probe; lane 3, nondigested probe; lanes GATC, sequence of the template clone using the same primer used to synthesize the probe. B, Probe using primer starting at position +92 to +76. Lane 1', nondigested probe; lane 2', protected fragment using 2  $\mu$ g poly(A<sup>+</sup>) mRNA; lane 3'-protected fragment using 5  $\mu$ g poly(A<sup>+</sup>) mRNA. C, Detailed scheme of S<sub>1</sub> nuclease analysis. (a), fragment of the first exon (*thick line*) and its 5'-flanking region (*thin line*) indicating localization of S<sub>1</sub> nuclease-protected fragments; (b) Probe synthesized by extension of the <sup>32</sup>-P labeled 25 bp primer starting at position -786; (c) fragment protected by the long mRNA species; (d) localization of the S<sub>1</sub> fragment protected by the short mRNA; the coding sequence is represented by the *thick line* while the *thin line* indicates the untranslated region; (e) probe synthesized by extension of the 17-nucleotide primer starting at position +92; (f) protected fragment of the short mRNA species.

poly(A)\* RNA was purified by two cycles of chromatography on oligo(dT)-cellulose columns (32).


Samples of poly(A)\* RNA were electrophoresed on a 1.2% agarose/2.2  $\,$  m formaldehyde gel alongside the BRL 0.24-9.5 kb RNA ladder, transferred to a nylon membrane (Hybond-N, Amersham), and hybridized to the random-primer (30) <sup>32</sup>P-labeled cDNA fragment corresponding to the *PstI-Sac1* region of the hpE<sub>2</sub>DH216 cDNA (2). The stringent hybridization and washing conditions were as described (2). Autoradiography was carried out at -80 C with two intensifying screens for up to 1 week.

## Acknowledgments

The authors wish to thank the staff of the Pathology Departments of Le Centre Hospitalier de l'Université Laval, l'HôtelDieu de Lévis, and L'Hôtel-Dieu de Québec as well as the following surgeons for their valuable and most appreciated assistance in collecting the human tissues: Drs. Jacques-Emile Rioux, Diogène Cloutier, Pierre Dupont, Jacques Mailloux, Daniel Cloutier, Jean Emond, Jean-Guy Houle, and Antoine Desgagné. We would also like to thank Mr. Guy Reimnitz for his skillful technical assistance as well as Mrs. Elaine Leclerc and Josée Poulin for preparation of this manuscript.

Received August 8, 1989. Revision received October 23, 1989. Accepted October 30, 1989.

Address requests for reprints to: Professor Fernand Labrie, MRC Group in Molecular Endocrinology, Research Centre,



**Fig. 5.** Tissue Distribution of Human 17β-HSD mRNAs

Poly(A)<sup>+</sup> RNA purified from the indicated human tissues was probed with the <sup>32</sup>P-labeled *PstI-SacI* fragment corresponding to the coding region of hpE<sub>2</sub>DH216 cDNA. With the exception of placenta 1 and 2 (2  $\mu$ g) and ovary 1 (5  $\mu$ g), all the lanes contained 20  $\mu$ g poly(A)<sup>+</sup> RNA. The blot was exposed to x-ray film for 1 week with the exception of placenta 1 which was exposed for 1 h.

Laval University Medical Centre, 2705 Laurier Boulevard, Québec G1V 4G2; Canada.

## REFERENCES

- Murdock GL, Chin CC, Offord RE, Bradshaw RA, Warren JC 1983 Human placental estradiol 17β-dehydrogenase. J Biol Chem 258:11460–11464
- Luu-The V, Labrie C, Zhao HF, Couët J, Lachance Y, Simard J, Leblanc G, Côté J, Bérubé G, Gagné R, Labrie F 1989 Characterization of cDNAs for human estradiol 17-β-dehydrogenase and assignment of the gene to chromosome 17: evidence of two mRNA species with distinct 5' termini in human placenta. Mol Endocrinol 3:1301– 1309
- Peltoketo H, Isomaa V, Mäentausta O, Vihko R 1988 Complete amino acid sequence of human placental 17βhydroxysteroid dehydrogenase deduced from cDNA. FEBS Lett 239:73-77
- Ryan KJ, Engel LL 1953 The interconversion of estrone and estradiol by human tissue slices. Endocrinology 52:287–291
- Inano H, Tamaoki B 1986 Testicular 17β-hydroxysteroid dehydrogenase: molecular properties and reaction mechanism. Steroids 48:3–26
- Tseng L, Stolee A, Gurpide E 1972 Quantitative studies on the uptake and metabolism of estrogens and progesterone by human endometrium. Endocrinology 90:390– 404
- 7. Weinstein GD, Frost P, Hsia SL 1968 In vitro interconver-

sion of estrone and  $17\beta\text{-estradiol}$  in human skin and vaginal mucosa. J Invest Derm 51:4–10

- 8. Milewich L, Hendricks TS, Romero LH 1982 Interconversion of estrone and estradiol- $17\beta$  in lung slices of the adult human. J Steroid Biochem 17:669–674
- 9. Breuer H, Knuppen R, Haupt M 1966 Metabolism of oestrone and oestradiol- $17\beta$  in human liver *in vitro*. Nature 212:76
- Bleau G, Roberts KD, Chapdelaine A 1974 The *in vitro* and *in vivo* uptake and metabolism of steroid in human adipose tissue. J Clin Endocrinol Metab 39:236–246
- 11. Jacobson GM, Hochberg RB 1968 17 $\beta$ -hydroxysteroid dehydrogenase from human red blood cells. J Biol Chem 243:2985–2994
- 12. Poulin R, Poirier D, Mérand Y, Thériault C, Bélanger A, Labrie F 1989 Extensive esterification of adrenal  $C_{19}-\Delta^5$  sex steroids to long-chain fatty acids in the ZR-75-1 human breast cancer cell line. J Biol Chem 264:9335–9343
- Lacoste D, Bélanger A, Labrie F 1989 Biosynthesis and degradation of androgens in human prostatic cancer cell lines. In: Bradlow H, Castagnetta L, d'Aquino S, Labrie F (eds) Steroid Formation, Degradation and Action in Peripheral Normal and Neoplastic Tissues. Ann New York Acad Sci, NY, in press
- Breathnach R, Chambon P 1981 Organization and expression of eucaryotic split genes coding for proteins. Annu Rev Biochem 50:349–383
- Benoist C, Chambon P 1981 *In vivo* sequence requirements of the SV40 early promoter region. Nature 290:304–310
- 16. Mathis DJ, Chambon P 1981 The SV40 early region TATA

box is required for accurate *in vitro* initiation of transcription. Nature 290:310–315

- Dynan WS, Tjian R 1985 Control of eukaryotic messenger RNA synthesis by sequence-specific DNA-binding proteins. Nature 316:774–778
- Letovsky J, Dynan W 1989 Measurement of the binding of transcription factor Spl to a single GC box recognition sequence. Nucleic Acid Res 17:2639–2653
- Dorn A, Bollekens J, Staub A, Benoist C, Mathis D 1987 A multiplicity of CCAAT box-binding proteins. Cell 50:863–872
- 20. Poulin R, Labrie F 1986 Stimulation of cell proliferation and estrogenic response by adrenal  $C_{19}$ - $\Delta^5$  steroids in the ZR-75-1 human breast cancer cell line. Cancer Res 46:4933-4937
- Labrie C, Simard J, Zhao HF, Bélanger A, Pelletier G, Labrie F 1989 Stimulation of androgen-dependent gene expression by the adrenal precursors dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology 124:2745–2754
- Labrie F, Dupont A, Bélanger A 1987 LHRH agonists and antiandrogens in prostate cancer. In: Ratliff TL, Catalona WJ (eds) Genitourinary Cancer. Martinus Nijhoff, Boston, pp 157–200
- Saez JM, De Peretti E, Morera AM, David M, Bertrand J 1971 Familial male pseudohermaphroditism with gynecomastia due to a testicular 17-ketosteroid reductase defect. I. Studies *in vivo*. J Clin Endocrinol Metab 32:604– 610
- Luu-The V, Lachance Y, Labrie C, Leblanc G, Thomas JL, Strickler RC, Labrie F 1989 Full length cDNA structure and deduced amino acid sequence of human 3β-hydroxy-

5-ene steroid dehydrogenase. Mol Endocrinol 3:1310-1312

- Sanger E, Milken S, Coulson AR 1977 DNA sequencing with chain terminating inhibitors. Proc Natl Acad Sci USA 74:5453–5467
- Tabor S, Richardson CC 1987 DNA sequence analysis with a modified bacteriophage T7 DNA polymerase. Proc Natl Acad Sci USA 84:4767–4771
- Greene JM 1987 Analysis of RNA structure and synthesis. In: Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman TG, Smith TA, Struhl K (eds) Current Protocols in Molecular Biology. Wiley and Sons, New York, pp 4.6.1– 4.6.5
- Aldridge J, Kunkel L, Bruns G, Tantravahi U, Lalande M, Brewster T, Moreau E, Wilson M, Bromley W, Roderick T, Latt SA 1984 A strategy to reveal high-frequency RFLPs along the human X chromosome. Am J Hum Genet 36:546–564
- Southern E 1975 Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol 98:503–517
- Feinberg AP, Vogelstein B 1983 A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 132:6–13
- Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ 1979 Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18:5294– 5299
- Aviv H, Leder P 1972 Purification of biologically active globin messenger RNA by chromatography on oligothymidylic acid-cellulose. Proc Natl Acad Sci USA 69:1408– 1412



275